ATE400297T1 - Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie - Google Patents

Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie

Info

Publication number
ATE400297T1
ATE400297T1 AT05713358T AT05713358T ATE400297T1 AT E400297 T1 ATE400297 T1 AT E400297T1 AT 05713358 T AT05713358 T AT 05713358T AT 05713358 T AT05713358 T AT 05713358T AT E400297 T1 ATE400297 T1 AT E400297T1
Authority
AT
Austria
Prior art keywords
diabetic nephropathy
microalbuminuria
ctgf
patients
treatment
Prior art date
Application number
AT05713358T
Other languages
English (en)
Inventor
Allan Flyvbjerg
Guangjie Guo
David Liu
Thomas Neff
Noelynn Oliver
William Usinger
Qingjian Wang
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE400297T1 publication Critical patent/ATE400297T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT05713358T 2004-02-11 2005-02-11 Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie ATE400297T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20

Publications (1)

Publication Number Publication Date
ATE400297T1 true ATE400297T1 (de) 2008-07-15

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05713358T ATE400297T1 (de) 2004-02-11 2005-02-11 Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie

Country Status (14)

Country Link
US (2) US20050214294A1 (de)
EP (2) EP1977762A1 (de)
CN (1) CN101884789A (de)
AT (1) ATE400297T1 (de)
AU (1) AU2005212371B2 (de)
CA (1) CA2555789A1 (de)
DE (1) DE602005008013D1 (de)
DK (1) DK1715890T3 (de)
ES (1) ES2311973T3 (de)
IL (1) IL177437A (de)
NZ (1) NZ549784A (de)
PL (1) PL1715890T3 (de)
PT (1) PT1715890E (de)
WO (1) WO2005077413A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112088B1 (de) * 1998-09-08 2010-10-27 Henry Ford Health System Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten
EP1891109A1 (de) 2005-05-05 2008-02-27 Fibrogen, Inc. Therapien von herzkreislauferkrankungen
ATE481094T1 (de) * 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
CA2673022A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN107083386A (zh) 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
DK2670411T3 (da) 2011-02-02 2019-05-13 Excaliard Pharmaceuticals Inc Antisense-forbindelser rettet mod bindevævsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN112512532B (zh) * 2018-07-31 2024-11-08 雷莫内克斯生物制药有限公司 用于抑制ctgf表达的组合物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
CA3142092A1 (en) * 2019-06-04 2020-12-10 Jiangsu Hengrui Medicine Co., Ltd. Anti-connective tissue growth factor antibody and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
EP1112088B1 (de) * 1998-09-08 2010-10-27 Henry Ford Health System Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
AU765133B2 (en) 1998-11-06 2003-09-11 Fibrogen, Inc. Connective tissue growth factor (CTGF) and methods of use
MXPA01005949A (es) * 1998-12-14 2002-09-18 Univ Miami Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2002366641A1 (en) 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
EP1497420A4 (de) 2002-04-30 2005-04-27 Alcon Inc Mittel, die die aktivität und/oder expression von bindegewebe-wachstumsfaktor (ctgf) regulieren, hemmen oder modulieren, als einzigartige mittel sowohl zur senkung des augeninnendrucks als auch zur behandlung von glaukomatösen retinopathien/optischen neuropathien
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP1687410A4 (de) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Für das nieren-targeting optimierte antisense-oligonukleotide

Also Published As

Publication number Publication date
EP1715890B1 (de) 2008-07-09
US20100291098A1 (en) 2010-11-18
CA2555789A1 (en) 2005-08-25
DE602005008013D1 (de) 2008-08-21
DK1715890T3 (da) 2008-11-17
EP1977762A1 (de) 2008-10-08
EP1715890A1 (de) 2006-11-02
PL1715890T3 (pl) 2009-01-30
HK1095762A1 (en) 2007-05-18
WO2005077413A1 (en) 2005-08-25
AU2005212371A1 (en) 2005-08-25
US20050214294A1 (en) 2005-09-29
US8314059B2 (en) 2012-11-20
ES2311973T3 (es) 2009-02-16
AU2005212371B2 (en) 2010-05-13
IL177437A (en) 2013-06-27
NZ549784A (en) 2008-06-30
PT1715890E (pt) 2008-10-17
IL177437A0 (en) 2006-12-10
CN101884789A (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
DE602005008013D1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
ATE521608T1 (de) Glucokinaseaktivatoren
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
DE602006007481D1 (de) 5-amino-4-hydroxy-7-(imidazo ä1,2-aü pyridin-6-ylmethyl)-8-methylnonamidderivate und verwandte verbindungen als renininhibitoren zur behandlung von bluthochdruck
NO20033949L (no) Sammensetning og fremgangsmåte til å behandle neoplastiske sykdommer assosiert med forhöyede matriks metalloproteinaseaktiviteter ved åbenytte katechinforbindelser
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
DE602005017626D1 (de) Antivirale verwendung von borinsäurekomplexen
DK1889920T3 (da) In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1715890

Country of ref document: EP